These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 6369720)

  • 1. Molecular markers in the diagnosis and prognosis of bladder cancer.
    Lange PH; Limas C
    Urology; 1984 Apr; 23(4 Suppl):46-54. PubMed ID: 6369720
    [No Abstract]   [Full Text] [Related]  

  • 2. Double blind comparison of T-antigen and ABO(H) cell surface antigens in bladder cancer.
    Vafier JA; Javadpour N; Worsham GF; O'Connell KJ
    Urology; 1984 Apr; 23(4):348-51. PubMed ID: 6369713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor markers in bladder cancer.
    Huben RP
    Urology; 1984 Mar; 23(3 Suppl):10-4. PubMed ID: 6367189
    [No Abstract]   [Full Text] [Related]  

  • 4. Tissue blood group ABH and Thomsen-Friedenreich antigens in human urinary bladder carcinoma.
    Weinstein RS; Miller AW; Coon JS
    Prog Clin Biol Res; 1984; 153():249-60. PubMed ID: 6382282
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple cell markers in bladder cancer. Principles and clinical applications.
    Javadpour N
    Urol Clin North Am; 1984 Nov; 11(4):609-16. PubMed ID: 6390912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Isoantigens ABH in bladder tumors as an indicator of malignant potential. IV. Correlation with Thomsen-Friedenreich antigen and CEA].
    Nasu Y; Kumon H; Matsumura Y; Ohmori H
    Nihon Hinyokika Gakkai Zasshi; 1986 Sep; 77(9):1511-8. PubMed ID: 3807094
    [No Abstract]   [Full Text] [Related]  

  • 7. Blood group isoantigens ABO (H) in transitional carcinoma of the bladder: a clinicopathological study.
    Cuadrado E; Rodriguez-Trinidad A; Blasco E; Torrado J; Lopez Garcia JA; Arozena F
    J Urol; 1986 Feb; 135(2):409-15. PubMed ID: 3511295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relations of clinicopathological findings to expression of ABH blood group and Thomsen-Friedenrich antigens in initially superficial papillary transitional cell carcinomas of the bladder developing subsequent malignant progression].
    Yamada T; Fukui I; Yokogawa M; Oshima H
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1049-53. PubMed ID: 3184579
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunohistochemical demonstration of blood group antigens in neoplastic and normal human urothelium: a comparison with standard red cell adherence.
    Flanigan RC; King CT; Clark TD; Cash JB; Greenfield BJ; Sniecinski IJ; Primus FJ
    J Urol; 1983 Sep; 130(3):499-503. PubMed ID: 6350617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent diagnostic modalities for bladder cancer.
    Sheinfeld J; Cordon-Cardo C; Bander NH
    Immunol Ser; 1990; 53():485-97. PubMed ID: 2151621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic markers in transitional carcinoma of the bladder].
    Blasco E; Gutiérrez-Hoyos A; Garrido C; Arozena F
    Arch Esp Urol; 1991; 44(1):47-52. PubMed ID: 2064423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis in carcinoma of the urinary bladder based upon tissue blood group abh and Thomsen-Friedenreich antigen status and karyotype of the initial tumor.
    Summers JL; Coon JS; Ward RM; Falor WH; Miller AW; Weinstein RS
    Cancer Res; 1983 Feb; 43(2):934-9. PubMed ID: 6848204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of blood group surface antigens of urinary bladder tumours using monoclonal antibodies with the avidin-biotin complex technique.
    Tan LB; Chiang C; Huang CH; Lin LM
    Int Urol Nephrol; 1992; 24(3):255-64. PubMed ID: 1399382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on multiple mucosal biopsy in patients with bladder cancer. 4. Evaluation of Thomsen-Friedenreich antigen in multiple mucosal biopsy and transitional cell carcinoma of the bladder].
    Igawa M
    Hinyokika Kiyo; 1986 Nov; 32(11):1663-76. PubMed ID: 3825815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The study on Thomsen-Friedenreich antigen in bladder tumor].
    Oda Y
    Hinyokika Kiyo; 1985 Mar; 31(3):407-18. PubMed ID: 3895852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic indicators of prognosis in bladder cancer: the importance of cell surface antigens.
    Richie JP; Blute RD; Waisman J
    J Urol; 1980 Jan; 123(1):22-4. PubMed ID: 6985979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood group isoantigen deletion and chromosomal abnormalities in bladder cancer.
    Pauwels RP; Schapers RF; Smeets AW; Jansen LE; Debruyne FM; Geraedts JP
    J Urol; 1988 Nov; 140(5):959-63. PubMed ID: 3050155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A, B, O (H) antigenic determinants in superficial transitional cell tumors of bladder.
    Selli C; Cozzolino F; Vercelli D; Mincione GP
    Urology; 1983 Feb; 21(2):132-4. PubMed ID: 6186066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and immunologic diagnosis of cancer. Renal and transitional carcinomas.
    Cordon-Cardo C
    Tumour Biol; 1987; 8(2-3):94-102. PubMed ID: 3329405
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study of the Thomsen-Friedenreich antigen in bladder tumors].
    Fukatsu H; Yamada H; Nonomura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Nishikawa E; Yamada Y
    Hinyokika Kiyo; 1988 Feb; 34(2):260-7. PubMed ID: 3376818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.